This suggests that K-312 may regulate the SKI-1/S1P or S2P cleavage and generation of the active nuclear forms of these SREBPs.11 Thus, K-312 decreases LDLc and PCSK9 levels, possibly serving as a new oral therapy for dyslipidemia and CVD. This evidence concerns the gene PCSK9 and metabolic syndrome.